EcoR1 Capital
Latest statistics and disclosures from EcoR1 Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are Prothena, Fibrogen, Dicerna Pharmaceuticals, Xencor, Kura Oncology, and represent 41.10% of EcoR1 Capital's stock portfolio.
- Added to shares of these 10 stocks: Arvinas Ord (+$55.02M), Assembly Biosciences (+$36.69M), Anaptysbio Inc Common (+$31.95M), Innate Pharma Adr (+$29.27M), BMRN (+$26.42M), Merus N V (+$21.86M), ACAD (+$21.39M), Neoleukin Therapeutics Inc (+$20.33M), Sage Therapeutics (+$12.52M), Selecta Biosciences (+$10.94M).
- Started 18 new stock positions in Urovant Sciences Ltd, Aclaris Therapeutics, ACAD, Iovance Biotherapeutics, Tcr2 Therapeutics Inc cs, Innate Pharma Adr, X4 Pharmaceuticals Inc, Sage Therapeutics, Corvus Pharmaceuticals, Arvinas Ord. Fate Therapeutics, Evolus Inc, Anaptysbio Inc Common, Selecta Biosciences, BMRN, Pieris Pharmaceuticals, Savara, Cytomx Therapeutics.
- Reduced shares in these 10 stocks: Spark Therapeutics (-$69.32M), Argenx Se (-$52.82M), Solid Biosciences (-$34.56M), Xencor (-$17.94M), Sarepta Therapeutics (-$14.29M), Gossamer Bio Inc (-$13.43M), Eiger Biopharmaceuticals (-$9.10M), Harpoon Therapeutics Inc (-$8.21M), Nextcure Inc (-$7.73M), Dicerna Pharmaceuticals (-$7.39M).
- Sold out of its positions in Autolus Therapeutics Plc spon ads, Cortexyme Inc, Curis Inc, Gossamer Bio Inc, Nextcure Inc, Regulus Therapeutics Inc, Sarepta Therapeutics, Solid Biosciences, Spark Therapeutics, Unity Biotechnology Inc. Zafgen.
- EcoR1 Capital was a net buyer of stock by $93.70M.
- EcoR1 Capital has $1.09B in assets under management (AUM), growing by 37.84%.
Companies in the EcoR1 Capital portfolio as of December 2019 quarter
| Company (Ticker) | Portfolio Weight | Share Count | Change in Shares | Price |
|---|---|---|---|---|
| Prothena | 13.67 | 9.43M | 15.83 | |
| Fibrogen | 8.52 | 2.17M | +11% | 42.89 |
| Dicerna Pharmaceuticals | 7.32 | 3.63M | -8% | 22.03 |
| Xencor | 6.24 | 1.98M | -20% | 34.39 |
| Kura Oncology | 5.34 | 4.24M | +4% | 13.75 |
| Ironwood Pharmaceuticals (IRWD) | 5.33 | 4.37M | -6% | 13.31 |
| Arvinas Ord | 5.04 | 1.34M | NEW | 41.09 |
| Assembly Biosciences | 4.48 | 2.39M | +301% | 20.46 |
| Neoleukin Therapeutics Inc | 4.42 | 3.92M | +72% | 12.32 |
| Morphic Hldg Inc Com | 3.39 | 2.15M | 17.16 | |
| Prevail Therapeutics Ord | 3.26 | 2.25M | -6% | 15.83 |
| Argenx Se | 2.97 | 202117 | -61% | 160.52 |
| Anaptysbio Inc Common | 2.93 | 1.97M | NEW | 16.25 |
| Innate Pharma Adr | 2.68 | 4.55M | NEW | 6.44 |
| BioMarin Pharmaceutical (BMRN) | 2.42 | 312500 | NEW | 84.55 |
| Merus N V | 2.22 | 1.72M | +937% | 14.08 |
| Atreca Inc Cl A Com | 2.10 | 1.48M | 15.47 | |
| ACADIA Pharmaceuticals (ACAD) | 1.96 | 500000 | NEW | 42.78 |
| Chiasma | 1.38 | 3.04M | 4.96 | |
| Harpoon Therapeutics Inc | 1.23 | 908547 | -37% | 14.79 |
| Sage Therapeutics | 1.15 | 173364 | NEW | 72.19 |
| Ultragenyx Pharmaceutical | 1.02 | 261554 | +324% | 42.71 |
| Selecta Biosciences | 1.00 | 4.60M | NEW | 2.38 |
| Exicure Inc | 0.93 | 3.54M | -35% | 2.86 |
| Pieris Pharmaceuticals | 0.84 | 2.54M | NEW | 3.62 |
| Fate Therapeutics | 0.81 | 451354 | NEW | 19.57 |
| Mirati Therapeutics | 0.77 | 65000 | +46% | 128.86 |
| Arcus Biosciences Incorporated | 0.68 | 729905 | -3% | 10.10 |
| Evolus Inc | 0.67 | 600000 | NEW | 12.17 |
| Eiger Biopharmaceuticals | 0.61 | 449338 | -57% | 14.90 |
| Savara | 0.59 | 1.43M | NEW | 4.48 |
| Iovance Biotherapeutics | 0.54 | 213647 | NEW | 27.68 |
| Rubius Therapeutics Inc | 0.46 | 525877 | +102% | 9.50 |
| Cyclerion Therapeutics Inc | 0.45 | 1.81M | +133% | 2.72 |
| X4 Pharmaceuticals Inc | 0.41 | 415400 | NEW | 10.70 |
| Corvus Pharmaceuticals | 0.37 | 737612 | NEW | 5.44 |
| Aclaris Therapeutics | 0.36 | 2.09M | NEW | 1.89 |
| Igm Biosciences Inc Com | 0.35 | 100000 | 38.16 | |
| Cytomx Therapeutics | 0.31 | 410000 | NEW | 8.31 |
| Tcr2 Therapeutics Inc cs | 0.31 | 239500 | NEW | 14.28 |
| Surface Oncology Inc | 0.22 | 1.30M | -15% | 1.88 |
| Vericel | 0.21 | 131001 | 17.40 | |
| Urovant Sciences Ltd | 0.04 | 26468 | NEW | 15.53 |
Download CSV 
Past 13F-HR SEC Filings by EcoR1 Capital
- EcoR1 Capital 2019 Q3 filed Nov. 14, 2019
- EcoR1 Capital 2019 Q2 filed Aug. 14, 2019
- EcoR1 Capital 2019 Q1 filed May 15, 2019
- EcoR1 Capital 2018 Q4 filed Feb. 14, 2019
- EcoR1 Capital 2018 Q3 filed Nov. 14, 2018
- EcoR1 Capital 2018 Q2 filed Aug. 14, 2018
- EcoR1 Capital 2018 Q1 filed May 15, 2018
- EcoR1 Capital 2017 Q4 filed Feb. 14, 2018
- EcoR1 Capital 2017 Q3 filed Nov. 14, 2017
- EcoR1 Capital 2017 Q2 filed Aug. 14, 2017
- EcoR1 Capital 2017 Q1 amended filed May 19, 2017
- EcoR1 Capital 2017 Q1 filed May 15, 2017
- EcoR1 Capital 2016 Q4 amended filed Feb. 15, 2017
- EcoR1 Capital 2016 Q4 amended filed Feb. 15, 2017
- EcoR1 Capital 2016 Q4 filed Feb. 14, 2017
- EcoR1 Capital 2016 Q3 filed Nov. 14, 2016
- EcoR1 Capital 2016 Q2 filed Aug. 15, 2016
- EcoR1 Capital 2016 Q1 filed May 16, 2016
- EcoR1 Capital 2015 Q4 filed Feb. 16, 2016